All posts tagged "The Janssen Pharmaceutical Companies of Johnson & Johnson"

CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study

At 16-months median follow-up, CARVYKTI® significantly improved progression-free survival compared to two standard treatments1 Data presented at the 2023 ASCO and EHA Annual Meetings and published...